Clinical Trial Update: A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of lumacaftor/ivacaftor on exercise tolerance in cystic fibrosis patients homozygous for F508del-CFTR; completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor/Ivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 4 | Status: COMPLETED | Results posted: 2019-06-17